Peter A Fasching Selected Research

Hormones (Hormone)

1/2022	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
1/2022	Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
11/2021	Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement.
11/2021	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes.
10/2021	Mammographic density and prognosis in primary breast cancer patients.
8/2021	Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
5/2021	Update Breast Cancer 2021 Part 1 - Prevention and Early Stages.
4/2021	Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients.
2/2021	Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
1/2021	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter A Fasching Research Topics

Disease

280	Breast Neoplasms (Breast Cancer) 03/2022 - 12/2005
151	Neoplasms (Cancer) 10/2022 - 12/2006
28	Triple Negative Breast Neoplasms 10/2022 - 06/2014
19	Ovarian Neoplasms (Ovarian Cancer) 06/2021 - 01/2011
14	Pathologic Complete Response 05/2021 - 04/2010
12	Circulating Neoplastic Cells 01/2020 - 07/2011
11	Carcinoma (Carcinomatosis) 04/2022 - 04/2010
11	Endometrial Neoplasms (Endometrial Cancer) 04/2021 - 01/2006
10	Ovarian Epithelial Carcinoma 01/2020 - 06/2011
9	Endometriosis 11/2021 - 11/2009
6	Neoplasm Metastasis (Metastasis) 10/2021 - 12/2008
5	Disease Progression 04/2021 - 01/2011
5	Inflammation (Inflammations) 01/2021 - 05/2013
5	Neutropenia 01/2018 - 01/2013
4	Cardiotoxicity 01/2022 - 04/2010
4	Pain (Aches) 08/2021 - 01/2010
4	Nausea 04/2019 - 01/2010
3	Amenorrhea 01/2021 - 10/2019
3	Genetic Risk Score 01/2020 - 04/2015
3	Vomiting 04/2019 - 07/2010
3	Exanthema (Rash) 01/2019 - 02/2012
2	Brain Neoplasms (Brain Tumor) 02/2022 - 12/2018
2	Leukopenia 01/2022 - 01/2018
2	Arthralgia (Joint Pain) 08/2021 - 10/2019

Drug/Important Bio-Agent (IBA)

78	Hormones (Hormone)IBA 01/2022 - 01/2007
58	Estrogen ReceptorsIBA 03/2022 - 01/2006
37	Biomarkers (Surrogate Marker)IBA 03/2022 - 04/2009
25	Progesterone Receptors (Progesterone Receptor)IBA 03/2022 - 12/2006
23	AnthracyclinesIBA 01/2022 - 04/2010
21	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2008
21	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2011
20	taxaneIBA 04/2022 - 04/2010
19	human ERBB2 proteinIBA 01/2022 - 04/2010
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 04/2010
17	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2008
16	Trastuzumab (Herceptin)FDA Link 01/2022 - 04/2010
15	Biological ProductsIBA 01/2020 - 08/2011
14	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 04/2010
14	ErbB Receptors (EGF Receptor)IBA 01/2021 - 04/2010
13	Estrogens (Estrogen)FDA Link 05/2021 - 12/2006
12	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2011
10	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 06/2014
10	MicroRNAs (MicroRNA)IBA 10/2018 - 06/2011
9	Tamoxifen FDA LinkGeneric 11/2021 - 01/2006
9	Messenger RNA (mRNA)IBA 01/2021 - 01/2008
9	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2012
9	Docetaxel (Taxotere)FDA Link 01/2019 - 04/2010
8	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2018
8	Transcription Factors (Transcription Factor)IBA 01/2020 - 04/2013
7	Letrozole (Femara)FDA LinkGeneric 01/2021 - 02/2014
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 01/2013
6	PlatinumIBA 04/2022 - 06/2014
6	ORALIT (ORS)IBA 03/2022 - 05/2009
6	Aromatase InhibitorsIBA 11/2021 - 01/2017
6	Capecitabine (Xeloda)FDA Link 06/2021 - 04/2010
6	pertuzumabIBA 06/2021 - 01/2019
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2022 - 03/2018
5	ribociclibIBA 01/2022 - 01/2018
5	Diphosphonates (Bisphosphonates)IBA 08/2021 - 01/2013
5	Immune Checkpoint InhibitorsIBA 05/2021 - 10/2016
5	Pharmaceutical PreparationsIBA 02/2021 - 05/2013
4	TabletsIBA 01/2022 - 01/2017
4	Zoledronic Acid (Zometa)FDA Link 08/2021 - 02/2014
4	Immunoconjugates (Immunoconjugate)IBA 05/2021 - 01/2019
4	Epidermal Growth Factor (EGF)IBA 01/2021 - 10/2011
4	Ado-Trastuzumab EmtansineIBA 10/2020 - 01/2019
4	exemestane (Aromasin)FDA Link 01/2020 - 01/2018
4	Everolimus FDA Link 02/2019 - 02/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2012
4	3' Untranslated Regions (3' UTR)IBA 11/2016 - 01/2014
4	RNA (Ribonucleic Acid)IBA 01/2016 - 01/2008
4	Oral ContraceptivesIBA 10/2015 - 01/2013
3	Denosumab FDA Link 01/2022 - 01/2017
3	130-nm albumin-bound paclitaxelIBA 01/2022 - 01/2019
3	Taxoids (Taxanes)IBA 10/2021 - 01/2011
3	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2021 - 01/2013
3	ChromatinIBA 01/2021 - 01/2015
3	Gemcitabine FDA Link 10/2020 - 09/2015
3	LigandsIBA 01/2020 - 01/2017
3	Aromatase (CYP19)IBA 01/2020 - 01/2008
3	Transforming Growth Factor-beta Type II ReceptorIBA 10/2016 - 02/2015
3	SteroidsIBA 12/2008 - 01/2007
2	pembrolizumabIBA 10/2022 - 01/2020
2	talazoparibIBA 02/2022 - 01/2019
2	Codon (Codons)IBA 01/2022 - 02/2016
2	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 01/2020
2	AntibodiesIBA 11/2021 - 09/2020
2	Cell-Free Nucleic AcidsIBA 11/2021 - 01/2013

Therapy/Procedure

94	Therapeutics 10/2022 - 12/2005
63	Drug Therapy (Chemotherapy) 10/2022 - 01/2010
59	Neoadjuvant Therapy 10/2022 - 04/2010
13	Adjuvant Chemotherapy 08/2021 - 01/2011
7	Mastectomy (Mammectomy) 01/2020 - 12/2008
5	Precision Medicine 06/2020 - 11/2018
4	Immunotherapy 11/2021 - 10/2019
4	Radiotherapy 10/2021 - 07/2014
4	Chemoprevention 01/2017 - 01/2007
3	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2018
3	Complementary Therapies (Alternative Medicine) 01/2020 - 01/2017
2	Palliative Care (Palliative Therapy) 02/2022 - 01/2017